IELSG Studies presented during 17-ICML (Lugano, June 13-17, 2023)

Oral presentations
IELSG37 – A randomized trial of observation versus radiotherapy in primary mediastinal B-cell lymphoma patients with complete metabolic response after standard immunochemotherapy
IELSG39 – The IELSG39 trial: efficacy of first-line chlamydia psitaci eradication with a six-month regimen of doxycycline in patients with stage-I MALT lymphoma of ocular adnexae
IELSG43 – Consolidative HCT-ASCT is superior to non-myeloablative chemo-immunotherapy in newly-diagnosed PCNSL – Updated results of the randomized phase II MATRix/IELSG43 trial
IELSG47 – Rituximab and ibrutinib combination is safe and effective in untreated splenic and nodal marginal zone lymphomas: planned subset analysis of the IESLG47/MALIBU phase II study

Poster presentation
IELSG35 – Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group